Product Description
von Willebrand Factor Antibody [VWF635] | 33-226 | ProSci
Host: Mouse
Reactivity: Human
Homology: N/A
Immunogen: A recombinant human protein fragment was used as the immunogen for this von Willebrand Factor antibody.
Research Area: Cancer, Stem Cell
Tested Application: WB, Flow, IHC, IF
Application: Flow Cytometry: 0.5-1 ug/million cells
IF: 0.5-1 ug/ml
WB: 0.5-1.0 ug/ml
IHC (FFPE) : 0.5-1.0 ug/ml for 30 minutes at RT (1)
Variations in protocols, secondaries and substrates may require the von Willebrand Factor antibody to be titered for optimal performance.
1. FFPE staining requires boiling tissue sections in 10mM Citrate Buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes.
Specificiy: N/A
Positive Control 1: N/A
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: N/A
Validation: N/A
Isoform: N/A
Purification: Protein G purified von Willebrand Factor antibody
Clonality: Monoclonal
Clone: VWF635
Isotype: IgG1, kappa
Conjugate: Unconjugated
Physical State: Liquid
Buffer: PBS with 0.1 mg/ml BSA and 0.05% sodium azide
Concentration: 0.2 mg/mL
Storage Condition: Aliquot and Store at 2-8˚C. Avoid freez-thaw cycles.
Alternate Name: VWF, Coagulation factor VIII VWF, F8VWF, VWD, Von Willebrand factor
User Note: Optimal dilutions for each application to be determined by the researcher
BACKGROUND:
von Willebrand Factor (vWF) is a glycoprotein produced by bone marrow cells and endothelial cells lining the inside surface of blood vessels. Its primary function is platelet adhesion, binding to Factor VIII, collagen and platelets, to coagulate blood at the site of wounding. The enzyme VWFCP, or vWF-cleaving protease, facilitates clotting by cutting the protein into subunits, increasing its binding capacity.
Deficiency or dysfunction of the protein increases the tendency of wounds to bleed, or to bleed more. Over 300 gene mutations have been identified and classified into three types. Type 1 von Willebrand Factor disease is characterized by reduced amounts in the bloodstream, Type 2 by reduced binding ability and Type 3 by a nonfunctional protein.